Information Provided By:
Fly News Breaks for September 19, 2018
CCXI
Sep 19, 2018 | 07:35 EDT
Canaccord analyst Michelle Gilson noted ChemoCentrx's partner Vifor announced they increased their ownership stake in the company and she views it as a vote of confidence in its rare renal franchise. The analyst said the weakness overlooks the avacopan strong clinical data for AAV and she expects a broad uptake of the drug if Phase 3 is successful. Gilson reiterated her Buy rating and $18 price target on ChemoCentryx shares.
News For CCXI From the Last 2 Days
There are no results for your query CCXI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.